Rogletimide (BioDeep_00000859111)

   


代谢物信息卡片


(+)-TRANS-1,2-CYCLOHEXANEDICARBOXYLICANHYDRIDE

化学式: C12H14N2O2 (218.1055224)
中文名称: (+/-) 3-乙基-3-(4-吡啶)-2,6-哌啶二酮
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCC1(CCC(=O)NC1=O)C2=CC=NC=C2
InChI: InChI=1S/C12H14N2O2/c1-2-12(9-4-7-13-8-5-9)6-3-10(15)14-11(12)16/h4-5,7-8H,2-3,6H2,1H3,(H,14,15,16)

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1740 - Aromatase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist

同义名列表

2 个代谢物同义名

(+)-TRANS-1,2-CYCLOHEXANEDICARBOXYLICANHYDRIDE; Rogletimide



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • P E Lønning. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Mar; 22(3):503-514. doi: 10.1093/annonc/mdq337. [PMID: 20616198]
  • M M Hefnawy. Stereoselective determination of pyridoglutethimide enantiomers in serum with a chiral cellulose-based high-performance liquid chromatographic column using solid phase extraction and UV detection. Journal of pharmaceutical and biomedical analysis. 2003 Apr; 31(5):999-1005. doi: 10.1016/s0731-7085(02)00702-1. [PMID: 12684112]
  • M C Etienne, W Oster, G Milano. Development and validation of a chiral high-performance liquid chromatography assay for rogletimide and rogletimide-N-oxide isomers in plasma. Cancer chemotherapy and pharmacology. 1996; 38(4):343-8. doi: 10.1007/s002800050493. [PMID: 8674157]
  • F A MacNeill, A L Jones, S Jacobs, P E Lønning, T J Powles, M Dowsett. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. British journal of cancer. 1992 Oct; 66(4):692-7. doi: 10.1038/bjc.1992.339. [PMID: 1419608]
  • E van Bakergem, R A van der Hoeven, W M Niessen, U R Tjaden, J van der Greef, G K Poon, R McCague. On-line continuous-flow dialysis thermospray tandem mass spectrometry for quantitative screening of drugs in plasma: rogletimide. Journal of chromatography. 1992 May; 598(2):189-94. doi: 10.1016/0021-9673(92)85047-w. [PMID: 1618979]
  • G K Poon, R McCague, L J Griggs, M Jarman, I A Lewis. Characterisation of metabolites of 3-ethyl-3-(4-pyridyl)-piperidine-2,6-dione, a potential breast cancer drug. Journal of chromatography. 1991 Dec; 572(1-2):143-57. doi: 10.1016/0378-4347(91)80479-v. [PMID: 1818050]
  • M Dowsett, F MacNeill, A Mehta, C Newton, B Haynes, A Jones, M Jarman, P Lonning, T J Powles, R C Coombes. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients. British journal of cancer. 1991 Nov; 64(5):887-94. doi: 10.1038/bjc.1991.420. [PMID: 1931611]
  • T Yamamoto, M Urabe, T Tamura, J Kitawaki, H Honjo, H Okada. Antitumor effect of pyridoglutethimide, an aromatase inhibitor, on 7,12-dimethylbenz(a)anthracene-induced mammary tumors of rat. Anticancer research. 1991 Nov; 11(6):1999-2002. doi: NULL. [PMID: 1776832]
  • B P Haynes, M Jarman, M Dowsett, A Mehta, P E Lønning, L J Griggs, A Jones, T Powles, R Stein, R C Coombes. Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer. Cancer chemotherapy and pharmacology. 1991; 27(5):367-72. doi: 10.1007/bf00688859. [PMID: 1847846]
  • M Dowsett. Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer. The Journal of steroid biochemistry and molecular biology. 1990 Dec; 37(6):1037-41. doi: 10.1016/0960-0760(90)90462-t. [PMID: 2149504]
  • P E Lønning, M Dowsett, T J Powles. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. Journal of steroid biochemistry. 1990 Mar; 35(3-4):355-66. doi: 10.1016/0022-4731(90)90241-j. [PMID: 2139151]
  • A Seago, P E Goss, L J Griggs, M Jarman. Pyridoglutethimide [3-ethyl-3-(4-pyridyl)-piperidine-2,6-dione], an analogue of aminoglutethimide. Metabolism and pharmacokinetics. Biochemical pharmacology. 1986 Sep; 35(17):2911-6. doi: 10.1016/0006-2952(86)90485-5. [PMID: 3741481]